Melanin affinity and its possible role in neurodegeneration

Journal of Neural Transmission

Volumn 120, Issue 12, 2013, Pages 1623-1630

  Karlsson, Oskar ^a   Lindquist, Nils Gunnar ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

ALS PDC; BMAA; Guam; MPTP; Neuromelanin; Parkinson's disease; Retinopathy

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MELANIN; NEUROMELANIN; NEUROTOXIN;

AMYOTROPHIC LATERAL SCLEROSIS; BINDING AFFINITY; DENDRITIC CELL; DENERVATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG PROTEIN BINDING; GUAM; HUMAN; MICROGLIA; NERVE CELL LESION; NERVE DEGENERATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RETINA PIGMENT EPITHELIOPATHY; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; HUMANS; MELANINS; NEURODEGENERATIVE DISEASES; NEUROTOXINS; PROTEIN BINDING;

EID: 84890548633     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1062-5     Document Type: Review

References (106)

1. Aubry AF (2002) Applications of affinity chromatography to the study of drug-melanin binding interactions. J Chromatogr B Analyt Technol Biomed Life Sci 768(1):67-74
2. Banack SA, Cox PA (2003) Biomagnification of cycad neurotoxins in flying foxes: implications for ALS-PDC in Guam. Neurology 61(3):387-389
3. Barden H, Levine S (1983) Histochemical observations on rodent brain melanin. Brain Res Bull 10(6):847-851
4. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr (2010) Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 67(3):347-352
5. Borenstein AR, Mortimer JA, Schellenberg GD, Galasko D (2009) The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 72(5):473
6. Bradley WG, Banack SA, Cox PA (2009) The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 72(5):473-474
7. Campbell RJ, Steele JC, Cox TA, Loerzel AJ, Belli M, Belli DD, Kurland LT (1993) Pathologic findings in the retinal pigment epitheliopathy associated with the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Ophthalmology 100(1):37-42
8. Claffey DJ, Ruth JA (2001) Amphetamine adducts of melanin intermediates demonstrated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Chem Res Toxicol 14(9):1339-1344
9. Coppedè F, Mancuso M, Siciliano G, Migliore L, Murri L (2006) Genes and the environment in neurodegeneration. Biosci Rep 26(5):341-367
10. Cox TA, McDarby JV, Lavine L, Steele JC, Calne DB (1989) A retinopathy on Guam with high prevalence in Lytico-Bodig. Ophthalmology 96(12):1731-1735
11. Cruz-Aguado R, Shaw CA (2009) The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 72(5):474
12. D'Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231(4741):987-989
13. D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH (1987) Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327(6120):324-326
14. Dayhaw-Barker P (2002) Retinal pigment epithelium melanin and ocular toxicity. Int J Toxicol 21(6):451-454
15. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5(6):525-535
16. Dencker L, Lindquist NG (1975) Distribution of labeled chloroquine in the inner ear. Arch Otolaryngol 101(3):185-188
17. Dencker L, Lindquist NG, Ullberg S (1975) Distribution of an 125I-labelled chloroquine analogue in a pregnant macaca monkey. Toxicology 5(2):255-265
18. Double KL, Gerlach M, Schunemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66(3):489-494
19. Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DK, Blackie J, Corbett A, Joffe R, Fung VS, Morris J, Riederer P, Gerlach M, Halliday GM (2009) Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 217(2):297-301
20. Duffy P, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia Nigra and locus Caeruleus in Parkinson's Disease. J Neuropathol Exp Neurol 24(3):398-414
21. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86(5):1142-1148
22. Fedorow H, Halliday GM, Rickert CH, Gerlach M, Riederer P, Double KL (2006) Evidence for specific phases in the development of human neuromelanin. Neurobiol Aging 27(3):506-512
23. Fenichel GM, Bazelon M (1968) Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology 18(8):817-820
24. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A (2009) Family history of melanoma and Parkinson disease risk. Neurology 73(16):1286-1291
25. Gaspar P, Berger B, Gay M, Hamon M, Cesselin F, Vigny A, Javoy-Agid F, Agid Y (1983) Tyrosine hydroxylase and methionine-enkephalin in the human mesencephalon. Immunocytochemical localization and relationships. J Neurol Sci 58(2):247-267
26. Greggio E, Bergantino E, Carter D, Ahmad R, Costin GE, Hearing VJ, Clarimon J, Singleton A, Eerola J, Hellstrom O, Tienari PJ, Miller DW, Beilina A, Bubacco L, Cookson MR (2005) Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. J Neurochem 93(1):246-256
27. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain: J Neurol 128(Pt 11):2654-2664
28. Halliday GM, Fedorow H, Rickert CH, Gerlach M, Riederer P, Double KL (2006) Evidence for specific phases in the development of human neuromelanin. J Neural Transm 113(6):721-728
29. Harrison WH, Gray RM, Solomon LM (1974) Incorporation of d-amphetamine into pigmented guinea-pig hair. Br J Dermatol 91(4):415-418
30. Herrero Hernandez E (2009) Pigmentation genes link Parkinson's disease to melanoma, opening a window on both etiologies. Med Hypotheses 72(3):280-284
31. Herrero MT, Hirsch EC, Kastner A, Ruberg M, Luquin MR, Laguna J, Javoy-Agid F, Obeso JA, Agid Y (1993) Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 56(2):499-511
32. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334(6180):345-348
33. Huang LZ, Parameswaran N, Bordia T, Michael McIntosh J, Quik M (2009) Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J Neurochem 109(3):826-837
34. Ishikawa A, Takahashi H (1998) Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J Neurol 245 Suppl 3 (11):4-9
35. Ito S (2003) A Chemist's View of Melanogenesis. Pigment Cell Res 16(3):230-236
36. Ito S, Wakamatsu K (2008) Chemistry of mixed melanogenesis - pivotal roles of dopaquinone. Photochem Photobiol 84(3):582-592
37. Jellinger KA, Kienzl E, Rumpelmaier G, Paulus W, Riederer P, Stachelberger H, Youdim MB, Ben-Shachar D (1993) Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol 60:267-272
38. Jimbow K (1995) Current update and trends in melanin pigmentation and melanin biology. Keio J Med 44(1):9-18
39. Karlsson O, Berg C, Brittebo EB, Lindquist NG (2009) Retention of the cyanobacterial neurotoxin beta-N-methylamino-l-alanine in melanin and neuromelanin-containing cells-a possible link between Parkinson-dementia complex and pigmentary retinopathy. Pigment Cell Melanoma Res 22(1):120-130
40. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 59(3):1080-1089
41. Kellner U, Kellner S, Weinitz S (2008) Chloroquine retinopathy: lipofuscin- and melanin-related fundus autofluorescence, optical coherence tomography and multifocal electroretinography. Doc Ophthalmol 116(2):119-127
42. Kemali M, Gioffre D (1985) Anatomical localisation of neuromelanin in the brains of the frog and tadpole. Ultrastructural comparison of neuromelanin with other melanins. J Anat 142:73-83
43. Kitamura Y, Shimohama S, Akaike A, Taniguchi T (2000) The parkinsonian models: invertebrates to mammals. Jpn J Pharmacol 84(3):237-243
44. Kopin IJ, Markey SP (1988) MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 11:81-96
45. Koutsilieri E, Lutz MB, Scheller C (2013) Autoimmunity, dendritic cells and relevance for Parkinson's disease. J Neural Transm 120(1):75-81
46. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979-980
47. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598-605
48. Larsson BS (1993) Interaction between chemicals and melanin. Pigment Cell Res 6(3):127-133
49. Larsson B, Tjalve H (1979) Studies on the mechanism of drug-binding to melanin. Biochem Pharmacol 28(7):1181-1187
50. Li J, Yang J, Zhao P, Li S, Zhang R, Zhang X, Liu D, Zhang B (2012) Neuromelanin enhances the toxicity of alpha-synuclein in SK-N-SH cells. J Neural Transm 119(6):685-691
51. Lindquist NG (1972) Accumulation in vitro of 35 S-chlorpromazine in the neuromelanin of human substantia nigra and locus coeruleus. Arch Int Pharmacodyn Ther 200(1):190-195
52. Lindquist NG (1973) Accumulation of drugs on melanin. Acta Radiol Diagn (Stockh) 325:1-92
53. Lindquist NG, Ullberg S (1972) The melanin affinity of chloroquine and chlorpromazine studied by whole body autoradiography. Acta Pharmacologica et Toxicologica 2(Suppl 2):1-32
54. Lindquist NG, Lyden-Sokolowski A, Larsson BS (1986) Accumulation of a parkinsonism-inducing neurotoxin in melanin-bearing neurons: autoradiographic studies on 3H-MPTP. Acta Pharmacologica et Toxicologica 59(2):161-164
55. Lindquist NG, Larsson BS, Lyden-Sokolowski A (1987) Neuromelanin and its possible protective and destructive properties. Pigment Cell Res 1(3):133-136
56. Lindquist NG, Larsson BS, Lyden-Sokolowski A (1988) Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci Lett 93(1):1-6
57. Liu R, Gao X, Lu Y, Chen H (2011) Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76(23):2002-2009
58. Lyden A, Larsson B, Lindquist NG (1982) Studies on the melanin affinity of haloperidol. Arch Int Pharmacodyn Ther 259(2):230-243
59. Lyden A, Bondesson U, Larsson BS, Lindquist NG (1983) Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans. Acta Pharmacol Toxicol (Copenh) 53(5):429-432
60. Ma QL, Chan P, Yoshii M, Ueda K (2003) Alpha-synuclein aggregation and neurodegenerative diseases. J Alzheimer's Dis (JAD) 5(2):139-148
61. Mars U, Larsson BS (1999) Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res 12(4):266-274
62. Marsden CD (1961) Pigmentation in the nucleus substantiae nigrae of mammals. J Anat 95:256-261
63. Marszall MP, Bucinski A, Gorynski K, Proszowska A, Kaliszan R (2011) Magnetic beads method for determination of binding of drugs to melanin. J Chromatogr A 1218(2):229-236
64. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLanney LE, Langston WJ, Janson AM (2004) Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 471(4):387-395
65. Oberlander U, Pletinckx K, Dohler A, Muller N, Lutz MB, Arzberger T, Riederer P, Gerlach M, Koutsilieri E, Scheller C (2011) Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC Neurosci 12:116
66. Ostergren A, Annas A, Skog K, Lindquist NG, Brittebo EB (2004) Long-term retention of neurotoxic beta-carbolines in brain neuromelanin. J Neural Transm 111(2):141-157
67. Palumbo A, Mars U, De Martino L, d'Ischia M, Napolitano A, Larsson BS, Prota G (1997) Selective incorporation of the prototype melanoma seeker thiourea into nascent melanin: a chemical insight. Melanoma Res 7(6):478-485
68. Pan T, Zhu J, Hwu WJ, Jankovic J (2012) The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS ONE 7(9):e45183
69. Plato CC, Galasko D, Garruto RM, Plato M, Gamst A, Craig UK, Torres JM, Wiederholt W (2002) ALS and PDC of Guam. Neurology 58(5):765-773
70. Plato CC, Garruto RM, Galasko D, Craig U-K, Plato M, Gamst A, Torres JM, Wiederholt W (2003) Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 157(2):149-157
71. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047
72. Potts AM (1962a) The concentration of phenothiazines in the eye of experimental animals. Invest Ophthalmol 1:522-530
73. Potts AM (1962b) Uveal pigment and phenothiazine compounds. Trans Am Ophthalmol Soc 60:517-552
74. Potts AM (1964a) Further studies concerning the accumulation of polycyclic compounds on uveal melanin. Invest Ophthalmol 3:399-404
75. Potts AM (1964b) The reaction of uveal pigment in vitro with polycyclic compounds. Invest Ophthalmol 3:405-416
76. Prota G (1992) Melanins and melanogenesis. Academic Press, Inc., San Diego
77. Reed DM, Torres JM, Brody JA (1975) Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam 1945-1972. Am J Epidemiol 101(4):302-310
78. Reed D, Labarthe D, Chen KM, Stallones R (1987) A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota. Am J Epidemiol 125(1):92-100
79. Ren G, Miao Z, Liu H, Jiang L, Limpa-Amara N, Mahmood A, Gambhir SS, Cheng Z (2009) Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med 50(10):1692-1699
80. Sanes DH, Reh TA, Harris WA (eds) (2006) Development of the nervous system, 2nd edn. Academic press Elsevier, Amsterdam
81. Sarna T (1992) Properties and function of the ocular melanin-a photobiophysical view. J Photochem Photobiol, B 12(3):215-258
82. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108(11):1263-1282
83. Shamoto-Nagai M, Maruyama W, Akao Y, Osawa T, Tribl F, Gerlach M, Zucca FA, Zecca L, Riederer P, Naoi M (2004) Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. J Neural Transm 111(10-11):1253-1265
84. Simon JD, Peles D, Wakamatsu K, Ito S (2009) Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function. Pigment Cell Melanoma Res 22(5):563-579
85. Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC (1987) Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237(4814):517-522
86. Spencer PS, Palmer V, Kisby G (2009) The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 72(5):474-475
87. Steele JC, McGeer PL (2008) The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 70(21):1984-1990
88. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 97(22):11869-11874
89. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW (1999) Parkinson disease in twins: an etiologic study. JAMA 281(4):341-346
90. Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW (2009) Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 66(9):1106-1113
91. Thomas B, Beal MF (2007) Parkinson's disease. Hum Mol Genet 16 Spec No. 2:R183-194
92. Tribl F, Arzberger T, Riederer P, Gerlach M (2007) Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. J Neural Transm Suppl 72:51-55
93. Tzekov R (2005) Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. Doc Ophthalmol 110(1):111-120
94. Ullberg S, Lindquist NG, Sjostrand SE (1970) Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature 227(5264):1257-1258
95. Wakamatsu K, Fujikawa K, Zucca FA, Zecca L, Ito S (2003) The structure of neuromelanin as studied by chemical degradative methods. J Neurochem 86(4):1015-1023
96. Wakamatsu K, Hu DN, McCormick SA, Ito S (2008) Characterization of melanin in human iridal and choroidal melanocytes from eyes with various colored irides. Pigment Cell Melanoma Res 21(1):97-105
97. Whiting MG (1963) Toxicity of cycads. Econ Bot 17:271-302
98. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R (2003) Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. Faseb J 17(3):500-502
99. Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Flensburg M, Petzinger GM, Widner H, Lew MF, Welsh M, Pedersen NL (2008) Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging 29(12):1765-1773
100. Xuan Q, Xu SL, Lu DH, Yu S, Zhou M, Ueda K, Cui YQ, Zhang BY, Chan P (2011) Increased expression of alpha-synuclein in aged human brain associated with neuromelanin accumulation. J Neural Transm 118(11):1575-1583
101. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 510(3):216-220
102. Zecca L, Zucca FA, Wilms H, Sulzer D (2003) Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 26(11):578-580
103. Zecca L, Wilms H, Geick S, Claasen J-H, Brandenburg L-O, Holzknecht C, Panizza M, Zucca F, Deuschl G, Sievers J, Lucius R (2008) Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol 116(1):47-55
104. Zhang W, Phillips K, Wielgus A, Liu J, Albertini A, Zucca F, Faust R, Qian S, Miller D, Chignell C, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong J-S, Sulzer D, Zecca L (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 19(1):63-72
105. Zhang W, Zecca L, Wilson B, Ren HW, Wang YJ, Wang XM, Hong JS (2013) Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front Biosci (Elite Ed) 5:1-11
106. Zhou W, Schaack J, Zawada WM, Freed CR (2002) Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res 926(1-2):42-50